Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6224)	11/6/1998 4:39:00 PM
From: Anthony Wong	Respond to of 9523

Pfizer Inc. Reiterated 'Buy' at Gerard Klauer Bloomberg News November 6, 1998, 3:11 p.m. ET Princeton, New Jersey, Nov. 6 (Bloomberg Data) -- Pfizer Inc. (PFE US) was reiterated ''buy'' by analyst Cynthia A. Beach at Gerard Klauer Mattison & Co. The 12-month target price is $120.00 per share. -- Andrew Bekoff in Princeton, New Jersey, (609)279-3652

To: BigKNY3 who wrote (6224)	11/6/1998 6:18:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Pfizer -3: Hopes To File Amended NDA For Zeldox In Late '99 11/06/98 Dow Jones News Service In the presentation to analysts, Pfizer executive vice president John Niblack said the company has no patent expirations on major products until five years from now. A press release issued after the presentation said there was one exception to that. Cardura, set to expire in 2000, was listed on a patent protection chart for Pfizer's major products. The next patent expiration will be in 2003 for the hypertension drug Procardia XL. Some of Pfizer's other major products under patent protection include Norvasc, an antihypertensive; Zithromax, an antibiotic; Diflucan, an anti-fungal treatment; and Zoloft, an anti-depressant. Lipitor, a cholesterol-lowering treatment launched last year in partnership with Warner-Lambert Co. (WLA), and Aricept, a treatment for Alzheimer's disease launched last year in partnership with Eisai, are also major products for the company. Of the four upcoming products Pfizer said it expects to launch, Celebrex, Tikosyn and Relpax are all under review at the Food and Drug Administration. The company hopes to file an amended new drug application for the fourth product, Zeldox, in late 1999. Pfizer received a non-approvable letter from the FDA in June for the antipsychotic drug. Pfizer ranked itself as the No. 3 pharmaceutical company in terms of sales, listing Merck & Co. (MRK) as the leader and Glaxo Wellcome PLC (GLX) as No. 2. Merck's sales in 1997 were $23.6 billion, while Glaxo's were GBP 7.98 billion.